Skip to main content

Improving Genome Editing Efficiency (IMGENE)

Objective

CRISPR genome editing technology is considered to become the greatest technological improvement in biomedical research since the invention of the polymerase chain reaction 25 years ago and pharmaceutical companies as well as academic research are eager to apply it. However, the efficiency of introducing defined changes into the genome by CRISPR is still low, currently limiting its application in basic research, industry and gene therapy. IMGENE unites expert European research groups of academia and industry to address by innovative and complementary approaches the low efficiency of precise genome editing using CRISPR technology. To our best knowledge, IMGENE is the only concerted approach to tackle the important problem of low genome editing efficiency of CRISPR in a multidisciplinary, intersectorial manner. The IMGENE consortium consisting of 6 academic and 1 industrial beneficiary (AstraZeneca), 2 industrial partners (Taconic; MilliporeSigma), and the patient organization Genetic Alliance, aims to improve the genome editing efficiency of CRISPR by research training of 8 ESRs to unleash the full potential of this technology. Combining complementary knowledge on protein chemistry, molecular biology, cellular biology, viral vectors, transgenic mice, gene therapy, and bioinformatics present in the network, IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.

Coordinator

KOBENHAVNS UNIVERSITET
Net EU contribution
€ 580 163,76
Address
Norregade 10
1165 Kobenhavn
Denmark

See on map

Region
Danmark Hovedstaden Byen København
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (6)

ASTRAZENECA AB
Sweden
Net EU contribution
€ 263 659,32
Address
Vastra Maelarhamnen
151 85 Sodertaelje

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
UNIVERSITAETSKLINIKUM FREIBURG
Germany
Net EU contribution
€ 249 216,48
Address
Hugstetter Strasse 49
79106 Freiburg

See on map

Region
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC
Portugal
Net EU contribution
€ 238 356,36
Address
Rua Alfredo Allen 208
4200 135 Porto

See on map

Region
Continente Norte Área Metropolitana do Porto
Activity type
Research Organisations
Non-EU contribution
€ 0,00
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
Net EU contribution
€ 255 374,28
Address
Albinusdreef 2
2333 ZA Leiden

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Germany
Net EU contribution
€ 249 216,48
Address
Robert Rossle Strasse 10
13125 Berlin

See on map

Region
Berlin Berlin Berlin
Activity type
Research Organisations
Non-EU contribution
€ 0,00
USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE
Czechia
Net EU contribution
€ 232 422,48
Address
Videnska 1083
142 20 Praha 4

See on map

Region
Praha Hlavní město Praha
Activity type
Research Organisations
Non-EU contribution
€ 0,00

Partners (3)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

Taconic GmbH
Germany
Net EU contribution
€ 0,00
Address

Cologne

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

Millipore Sigma
United States
Net EU contribution
€ 0,00
Address

Massachusetts

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

GENETIC ALLIANCE UK LTD
United Kingdom
Net EU contribution
€ 0,00
Non-EU contribution
€ 0,00